Patent · US Active

Systems and methods for optimized patient specific tissue engineering vascular grafts

US12115282B2 · kind B2 · utility

0Cited by
60References
15Claims
0Family size

Assignee

Inventors

Key dates

Filing dateDec 8, 2022
Grant dateOct 15, 2024
Priority date
Expiry dateJan 26, 2043

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61L2300/416
  • WIPO fieldMedical technology
  • WIPO sectorInstruments

Abstract

It has been established that optimizing cell seeding onto tissue engineering vascular grafts (TEVG) is associated with reduced inflammatory responses and reduced post-operative stenosis of TEVG. Cell seeding increased TEVG patency in a dose dependent manner, and TEVG patency improved when more cells were seeded, however duration of incubation time showed minimal effect on TEVG patency. Methods of engineering patient specific TEVG including optimal numbers of cells to maintain graft patency and reduce post-operative stenosis are provided. Closed, single-use customizable systems for seeding TEVG are also provided. Preferably the systems are custom-designed based on morphology of the patient specific graft, to enhance the efficacy of cell seeding.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.